According to the Complaint, Indivior PLC and its subsidiaries develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The Company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia.

The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On July 30, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on September 30.

On February 8, 2021, the parties entered into a Stipulation and Agreement of Settlement. The Court granted preliminary approval of the Settlement on September 16. On January 6, 2022, the Court granted final approval of the Settlement and entered Final Judgment.

On November 21, 2023, the Court issued an Order approving Lead Plaintiff's Motion for Disbursement of Settlement Funds.